About Steve Gorlin
Steve Gorlin is a vice chairman & president at CoRegen.
Steve Gorlin reports to the SEC as a director, officer or major shareholder of 8 public companies, including Biovie (BIVI), ImmunityBio (IBRX) and Polarityte (PTE).
Steve Gorlin first appears on SEC filings in 2006.
Experience
This experience comes from SEC filings. The years are when the filings name Steve Gorlin in the role, so the role may have started earlier or lasted longer.
CoRegen, Inc.
Vice Chairman & President
2024 – 2026 · Houston, TX
Develops immune cell therapies for people with cancer.
BI
Biovie Inc.
Director
2020 – 2023 · Public company (BIVI)
II
ImmunityBio, Inc.
Director
2015 – 2020 · Public company (IBRX)
PI
Polarityte, Inc.
Director
2017 – 2019 · Public company (PTE)
OI
Ontrak, Inc.
Director
2015 – 2018 · Public company (OTRK)
II
Innoveren Scientific, Inc.
Director
2015 – 2017 · Public company (IVRN)
MI
Mimedx Group, Inc.
Chairman of the Board
2008 – 2013 · Public company (MDXG)
MI
Midatech Pharma US Inc.
Director
2008 – 2012 · Public company (DARA)
MI
Medivation, Inc.
Director and 10% owner
2006 · Public company (MDVN)
Key Colleagues at Startups
The people Steve Gorlin works with at each company, as listed on that company's latest Form D.
CoRegen, Inc. · Form D, Feb 26, 2026
JS
Jonathan Simons
Board Member
BM
Bert O'Malley
Director
Suneet Varma
Chairman of the Board
WP
William Haseltine, PhD.
Director
Sonja Nelson
Chief Financial Officer
Sonal Gupta
Chief Medical Officer
LF
Lee Fleisher
Board Member
EJ
Edward Benz, Jr.
Director
Peter Gelinas
Chief Technical Officer